ESR1 and breast carcinoma: To identify the markers associated with resistance to taxane-based neoadjuvant chemotherapy in ER+/HER2- breast cancer, we analyzed GSE20194, GSE20271, GSE25055, GSE25065, and GSE32646 datasets in GEO2R.